Table 6.
Change in estimated glomerular filtration rate from baseline according to prior treatment status
| Treatment group | Baseline, (n) |
Change in eGFR (CKD-EPI) from baseline to: | ||
|---|---|---|---|---|
| Month 12, n, median (range) (mL/min/1.73 m2) |
Month 24, n, median (range) (mL/min/1.73 m2) |
Month 36, n, median (range) (mL/min/1.73 m2) |
||
| Overall | 360 | 249 −0.67 (−41.5, 38.54) P = 0.044 |
217 −0.60 (−61.03, 37.86) P = 0.681 |
204 −2.61 (−48.78, 34.91) P = 0.033 |
| Treatment-naive | 143 | 91 −0.77 (−37.91, 22.00) P = 0.015 |
79 −1.50 (−36.02, 29.86) P = 0.240 |
75 −5.55 (−48.78, 34.54) P = 0.009 |
| Treatment-experienced | 217 | 158 −0.11 (−41.05, 38.54) P = 0.48 |
138 0.37 (−61.03, 37.86) P = 0.762 |
129 −1.69 (−40.78, 34.91) P = 0.536 |
| Prior ADV | 157 | 117 0.03 (−41.05, 38.54) P = 0.534 |
101 1.18 (−61.03, 37.86) P = 0.700 |
101 −1.02 (−38.50, 33.87) P = 0.888 |
| No prior ADV | 203 | 132 −0.72 (−37.91, 33.18) P = 0.032 |
116 −1.20 (−50.07, 29.86) P = 0.327 |
103 −5.55 (−48.78, 34.91) P = 0.008 |
ADV adefovir, CKD-EPI chronic kidney disease epidemiology collaboration, eGFR estimated glomerular filtration rate
P values calculated using Fisher’s exact test (two-sided)